Depression Drug (Benzodiazepines, SNRIs, TCAs, TeCAs, Atypical Antipsychotics, Monoamine Oxidase inhibitors and Others) Market : Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2014 - 2020

The report covers forecast and analysis for the depression drug market on a global and regional level. The study provides historic data of 2014 along with a forecast from 2015 to 2020 based revenue (USD Million). The study includes drivers and restraints for the depression drug market along with the impact they have on the demand over the forecast period. Additionally, the report includes study of opportunities available in the depression drug market on a global level.

In order to give the users of this report a comprehensive view on the depression drug market, we have included a detailed competitive scenario, and product portfolio of key vendors. To understand the competitive landscape in the market, an analysis of Porter’s five forces model for the depression drug market has also been included. The study encompasses a market attractiveness analysis, wherein application segments are benchmarked based on their market size, growth rate and general attractiveness.

The study provides a decisive view on the depression drug market by segmenting the market based class and region. The different classs of depression also have different symptoms, including major or clinical depressive disorder, postpartum depression, dysthymic disorder, psychotic depression and seasonal affective disorder. Depending upon class global depression drug market is segmented as anticonvulsants, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors (SSRIs), beta-blockers, benzodiazepines, tetracyclic antidepressants (TeCAs) and monoamine oxidase inhibitors (MAOIs) among others. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East and Africa with its further bifurcation into major countries including U.S. Germany, France, UK, China, Japan, India and Brazil.

The report covers detailed competitive outlook including company profiles of the key participants operating in the global market. Key players profiled in the report include Forest Laboratories, AstraZeneca, GlaxoSmithKline, Abbott Laboratories, H. Lundbeck, Novartis, SK Biopharmaceuticals, Naurex Merck & Co., and Eli Lilly and Company.

This report segments the global drug depression market as follows:

Global Depression Drug Market: Class Segment Analysis

• Atypical Antipsychotics
• Tricyclic Antidepressants
• Selective Serotonin Reuptake Inhibitors
• Serotonin-Norepinephrine Reuptake Inhibitors
• Tetracyclic Antidepressants
• Monoamine Oxidase inhibitors
• Benzodiazepines
• Others

Global Depression Drug Market: Regional Segment Analysis

• North America

  • U.S.

• Europe

  • UK
  • France
  • Germany

• Asia Pacific

  • China
  • Japan
  • India

• Latin America

  • Brazil

• Middle East and Africa